Tampa General Hospital’s Cancer Institute features a brand new, state-of-the-art Bone Marrow Transplant (BMT) and Cell Therapies unit. This innovative addition to TGH’s world-class cancer center specializes in treating patients with aggressive blood cancers, such as leukemias, lymphomas, multiple myeloma and other types of cancer.
At TGH, we recognize that you have a choice when it comes to cancer treatment — and you deserve the best. We’re proud to have earned a “high performing” designation for cancer care from U.S. News & World Report for 2023-24, ranking TGH among the top 10% of U.S. hospitals. In addition to being recognized for our rigorous, high-quality standards of care, we participate in many groundbreaking clinical trials, allowing our patients to have access to incredible new treatments on a regular basis.
What Is Cellular Cancer Therapy?
Bone marrow transplant is also known as stem cell therapy (SCT) and is a type of immunotherapy. This form of cellular cancer therapy boosts the immune system’s ability to fight cancer more effectively. We offer:
Autologous and Allogeneic Stem Cell Transplants
An autologous stem cell transplant is when a patient’s own healthy blood stem cells are collected. After the patient undergoes chemotherapy, the stem cells are reintroduced to the body to replace diseased bone marrow. Alternatively, allogeneic stem cell transplants use donor stem cells in the same process. Stem cell transplants may be effective treatment options for patients who are producing enough healthy bone marrow cells.
CAR-T Infusion Therapy
Innovative CAR-T therapy involves using a patient’s own T cells, a type of white blood cell that helps protect the body from infection. Our expert cancer geneticists then engineer chimeric antigen receptors (CARs) on the surface of T cells. When these are reintroduced into the patient, the T cells can better target and attack specific markers on the patient’s own cancer cells. This is a highly personalized and targeted therapy that improves the curative rate for patients with hybrid lymphomas and other aggressive cancers.